Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Clin Cancer Res. 2010 May 14;16(13):3409–3419. doi: 10.1158/1078-0432.CCR-10-0644

Figure 4. mAb-mediated depletion of Ly6G+ cells, but not CD25+ cells, inhibit the growth of SB-induced gliomas.

Figure 4

(A and B) Ifnar1−/− or WT mice with developing gliomas received i.p. injections of anti-Ly6G mAb (RB6-8C5; 0.25 mg/dose) or control IgG on days 21, 23, 25, and 27 after tumor induction. (A) The mice were sacrificed, and BILs were isolated for CD11b+Ly6G+ subpopulations. (B) Symptom-free survival was monitored. (C and D) Ifnar1−/− or WT mice with developing gliomas received i.p. injections of anti-CD25 mAb (PC61; 0.25 mg/dose) or control IgG on days 21 and 24 after tumor induction. (C) The mice were sacrificed, and BILs were isolated for CD4+FoxP3+ subpopulations. (D) Symptom-free survival was monitored.